Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal

Editorial

Suzanne E Dahlberg et al. J Clin Oncol. 2008.

. 2008 Sep 10;26(26):4233-5.

doi: 10.1200/JCO.2008.17.0837.

No abstract available

Comment on

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M. Maruyama R, et al. J Clin Oncol. 2008 Sep 10;26(26):4244-52. doi: 10.1200/JCO.2007.15.0185. J Clin Oncol. 2008. PMID: 18779611 Clinical Trial.
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.
Crinò L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, Speake G, Cullen M. Crinò L, et al. J Clin Oncol. 2008 Sep 10;26(26):4253-60. doi: 10.1200/JCO.2007.15.0672. J Clin Oncol. 2008. PMID: 18779612 Clinical Trial.